TORONTO, ONTARIO--(Marketwire - Oct. 13, 2011) - Easton Pharmaceuticals (OTC:EAPH), a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products announced today the appointment of Daniel Bagi, MD as consultant to spearhead Viorra regulatory, patent and product launch initiatives in Mexico.

Dr. Bagi is the lead contact with BMV Medica S.A. de C.V. (BMV) a regulatory & licensing consultantancy company in Mexico, which has been engaged to begin the process of submitting applications to obtain regulatory approvals for its first product, VIORRA, in that country. Dr. Bagi has developed substantial relationships in Mexico for other products over the last 20+ yrs. In addition, Dr. Bagi understands the local regulatory process and will be working closely with BMV to have Viorra approved for sale. With his astute understanding of the market in Mexico, Dr. Bagi will assist Easton Pharmaceuticals on all aspects of marketing Viorra and other Easton products. Along with his Mexican contacts, Dr. Bagi has nurtured contacts in markets within East Asia, which the company anticipates on eventually utilizing. Aside from his appointment as consultant to Easton Pharmaceuticals, the company has entered into discussions with Dr. Bagi for a director and officer position within the company.

Dr. Bagi and BMV estimate the regulatory process to require six to seven months after filing until a marketing approval is obtained. In parallel with the regulatory filing, Easton Pharmaceuticals, through the efforts and relationships of Dr. Bagi, has begun talks with several large companies with a presence in sales and marketing in the women's health, sexual arousal disorder and the sexual wellness markets. Easton believes, barring any long financing delays, that these regulatory and commercial alliance initiatives running in parallel will enable a timely, successful launch of Viorra in Mexico in 2012.

"We are very pleased with the appointment of Dr. Daniel Bagi as a chief consultant who with his many contacts in Mexico, knowledge and belief in our Viorra product, and well established credentials will prove to be a huge asset to the company," stated John Easton, Easton Pharmaceuticals' CEO and Chairman of the Board.

Viorra is an over-the-counter aid for the treatment to restore and improve vaginal elasticity and moisture which has shown to give a positive effect on women's sexual desire and arousal, helping to alleviate FSAD (Female Sexual Arousal Disorder). Viorra is a topical, daily-use product formulated with ingredients classified by the FDA as Generally Recognized as Safe.

About Easton Pharmaceuticals

Toronto-based Easton Pharmaceuticals is a specialty pharmaceutical company that designs, develops, and markets a premium array of topically-delivered therapeutic healthcare products, focused on skin and circulatory conditions that impact a large and expanding number of consumers including health issues related to male and female sexual dysfunction, scar and stretch marks, cellulite and varicose veins, the world annual market for these conditions is in excess of $10 billion.

The company's proprietary gel formulation is an innovative and unique transdermal delivery system. Easton Pharmaceuticals' flagship product, VIORRA, is an over-the-counter aid for the treatment to restore and improve vaginal elasticity and moisture, which has a very positive effect on women's sexual desire and arousal, helping alleviate FSAD (Female Sexual Arousal Disorder) the world annual market for these female conditions are in excess of $2 billion. VIORRA is a topical, daily-use product classified by the FDA as containing Generally Recognized as Safe ingredients.

For More Information Visit [ http://www.eastonpharma.com ]

Safe Harbor

This news release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when used in the preceding of discussion, the words "pleased," "plan," "confident that," "believe," "expect," or "intent to" and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing and other risks and uncertainties as stated in the company's financial reports and filings which all investors are urged to review.